$5.1B deal: GSK buying ovarian cancer drug developer
In a major move to boost its oncology product pipeline, GlaxoSmithKline entered into a definitive agreement Monday to acquire Boston-area biopharmaceutical company Tesaro for $5.1 billion.
Tesaro (NASDAQ: TSRO) of Waltham, Mass., markets the ovarian cancer therapy Zejula, which is approved in the United States and Europe. The company is also conducting clinical trials that if successful could lead to an expanded use of the drug, as a monotherapy and in combination with other ovaria n cancer treatments.
“The…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: John George Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Cancer Therapy | Clinical Trials | Health Management | Ovarian Cancer | Ovaries | USA Health